While there were fewer gynecologic cancer sessions on Day 3, Sunday June 4th there were two important sessions regarding the use of PARP inhibitors and trial results for a drug to teat platinum resistant ovarian cancer drug which may be change practice.
Parp Inhibitor Optimal Selection and Toxicity Management
Dr Tew - Status updates on Parp use
Dr Friedlander- Real World Experience in Managing PARP Toxicities
Susan Feinberg (FORCE) - Living on a PARPi
I wish I had been able to be in the room when this session took place. I could feel the excitement from the Tweets being posted. This is the first trial to show overall survival benefit in platinum resistant ovarian cancer! This is practice changing.
Wow! Amazing to see an #OverallSurvival benefit for Mirvetuximab for patients with platinum resistant #OvarianCancer
— Megan Hutchcraft MD (@MeganLeigh127) June 4, 2023
🚨 new standard of care alert 🚨 #GynCSM #ASCO23
Congrats to the investigators and patients who made this #research possible! @ASCO pic.twitter.com/ojYBIDKYS0
🚨Amazing to see ⬆️ in overall survival for mirvetixumab in FOLR1 positive platinum resistant #ovariancancer. Absolutely new standard of care!! 👏 #gyncsm #ASCO23 pic.twitter.com/yweWSh5qES
— Eleonora Teplinsky, MD (@drteplinsky) June 4, 2023
I shared tweets others wrote about the MIRASOL trial (mirvetixumab in FOLR1 positive platinum resistant #ovariancancer ) but... this slide says it all . #ASCO23 #gyncsm pic.twitter.com/Sif0gn76a8
— Dee Sparacio (@womenofteal) June 4, 2023
Here is a slide of the overall survival MIRV 16.46 months vs investigator choice of treatment 12.75 months.
Stop by tomorrow for highlights from my last day of ASCO - Day 4 .
Dee
Every Day is a Blessing
No comments:
Post a Comment